Cetuximab or Panitumumab versus Bevacizumab in the treatment of first line RAS wild type colorectal cancer: pooled analysis of randomized clinical trials.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e14634-e14634
Author(s):  
Emiliano Tamburini ◽  
Britt Rudnas ◽  
Mario Nicolini ◽  
Stefania Nicoletti ◽  
Manuela Fantini ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Pooled Analysis ◽  
Wild Type ◽  
First Line

scholarly journals First-Line Maintenance Treatment in Metastatic Colorectal Cancer (mCRC): Quality and Clinical Benefit Overview

2021 ◽  
Vol 10 (3) ◽  
pp. 470
Author(s):  
Marta Martín-Richard ◽  
Maria Tobeña
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Clinical Benefit ◽  
Maintenance Treatment ◽  
Randomized Clinical Trials ◽  
Line Treatment ◽  
First Line ◽  
Design Quality ◽  
Primary Endpoints ◽  
First Line Treatment

Different strategies of maintenance therapy (sequential CT, intermittent CT, intermittent CT and MAbs, or de-escalation MAbs monotherapy) after first-line treatment are undertaken. Many randomized clinical trials (RCT), which evaluated these approaches, suffer from incorrect design, heterogenous primary endpoints, inadequate size, and other methodology flaws. Drawing any conclusions becomes challenging and recommendations are mainly vague. We evaluated those studies from another perspective, focusing on the design quality and the clinical benefit measure with a more objective and accurate methodology. These data allowed a clearer and more exact overview of the statement in maintenance treatment.

Role of radiofrequency ablation in the treatment of liver metastases from colorectal cancer: Pooled analysis of randomized clinical trials.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e14557-e14557
Author(s):  
Fabrizio Drudi ◽  
Emiliano Tamburini ◽  
Manuela Fantini ◽  
Antonio Polselli ◽  
Lucia Stocchi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Radiofrequency Ablation ◽  
Liver Metastases ◽  
Randomized Clinical Trials ◽  
Pooled Analysis

Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials

2009 ◽  
Vol 27 (2) ◽  
pp. 199-205 ◽  
Author(s):  
Fairooz F. Kabbinavar ◽  
Herbert I. Hurwitz ◽  
Jing Yi ◽  
Somnath Sarkar ◽  
Oliver Rosen
Keyword(s):  
Colorectal Cancer ◽  
Adverse Events ◽  
Older Patients ◽  
Statistical Power ◽  
Randomized Clinical Trials ◽  
Objective Response ◽  
Progression Free Survival ◽  
Pooled Analysis ◽  
First Line ◽  
Younger Patients

PurposeColorectal cancer (CRC) occurs predominantly in older persons. To provide more statistical power to assess risk/benefit in older patients, we examined the clinical benefit of bevacizumab (BV) plus fluorouracil-based chemotherapy in first-line metastatic CRC (mCRC) treatment in patients aged ≥ 65 years, using data pooled from two placebo-controlled studies.Patients and MethodsPooled efficacy data for 439 patients ≥ 65 years old randomized to BV plus chemotherapy (n = 218) or placebo plus chemotherapy (n = 221) in study 1 and study 2 were retrospectively analyzed on an intent-to-treat basis for overall survival (OS), progression-free survival (PFS), and objective response. Safety analysis was based on reports of targeted adverse events in treated patients.ResultsMedian OS with BV plus chemotherapy was 19.3 v 14.3 months with placebo plus chemotherapy (hazard ratio [HR] = 0.70; 95% CI, 0.55 to 0.90; P = .006). Patients treated with BV plus chemotherapy had a median PFS of 9.2 v 6.2 months for placebo plus chemotherapy patients (HR = 0.52; 95% CI, 0.40 to 0.67; P < .0001). The objective response rate was 34.4% with BV plus chemotherapy versus 29.0% with placebo plus chemotherapy (difference not statistically significant). Rates of BV-associated adverse events in the pooled BV plus chemotherapy group were consistent with those reported in the overall populations for the two studies.ConclusionAnalysis of pooled patient cohorts age ≥ 65 years from two similar trials in mCRC indicates that adding bevacizumab to fluorouracil-based chemotherapy improved OS and PFS, similar to the benefits in younger patients. Also, the risks of treatment do not seem to exceed those in younger patients with mCRC.

scholarly journals A pooled analysis of the duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine

2019 ◽  
Author(s):  
MT Bretscher ◽  
P Dahal ◽  
J Griffin ◽  
K Stepniewska ◽  
Q Bassat ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Drug Sensitivity ◽  
Population Level ◽  
Pooled Analysis ◽  
Additional Benefit ◽  
Post Treatment ◽  
Line Treatment ◽  
Wild Type ◽  
First Line ◽  
First Line Treatment

AbstractArtemether-lumefantrine (AL) and artesunate-amodiaquine (AS-AQ) are the most commonly-used treatments against Plasmodium falciparum malaria in Africa. The lumefantrine and amodiaquine partner drugs may provide differing durations of post-treatment prophylaxis, an important additional benefit to patients. Analyzing 4214 individuals from clinical trials in 12 sites, we estimated a mean duration of post-treatment protection of 13.0 days (95% CI 10.7-15.7) for AL and 15.2 days (95% CI 12.8-18.4) for AS-AQ after allowing for transmission intensity. However, the duration varied substantially between sites: where wild type pfmdr1 86 and pfcrt 76 parasite genotypes predominated, AS-AQ provided ∼2-fold longer protection than AL. Conversely, AL provided up to 1.5-fold longer protection than AS-AQ where mutants were common. We estimate that choosing AL or AS-AQ as first-line treatment according to local drug sensitivity could alter population-level clinical incidence of malaria by up to 14% in under-five year olds where malaria transmission is high.

Sign in / Sign up

Export Citation Format

Share Document